Vivimed Labs Stock Prediction 2026: Expert Analysis, Forecast Scenarios and Full Stock Review
- June 18, 2026
- Posted by: Kunal Singla
- Category: News
Vivimed Labs (NSE:VIVIMEDLAB) CMP: Rs 95 (2026). Sector: Pharmaceuticals and Healthcare. JM Financial: Neutral Rs 115. Kotak Securities: Neutral Rs 102. Consensus: Rs 109. Bull: Rs 115. Bear: Rs 92.
The Vivimed Labs stock prediction for 2026 from leading brokerages covers a range reflecting sector dynamics, earnings trajectory and the macro environment. All estimates may or may not be achieved. Treat any Vivimed Labs share price prediction as one data point and not as a guarantee of future performance.
This article reviews every dimension of the Vivimed Labs stock forecast analysts are tracking, including key drivers, bull and bear scenarios and the primary risks. Verify all figures with the latest brokerage reports before any investment decision.
Click Here – Get Free Investment Predictions
What Analysts Predict for Vivimed Labs Stock in 2026
Analyst consensus on the Vivimed Labs stock prediction for 2026 is tracked by leading brokerages. The table below shows the latest available data from JM Financial and Kotak Securities. All figures are sourced from publicly available research and should be verified before publishing.
| Brokerage | Rating | Vivimed Labs Stock Prediction (Rs) | Updated |
|---|---|---|---|
| JM Financial | Neutral | Rs 115 | 2026 |
| Kotak Securities | Neutral | Rs 102 | 2026 |
| Analyst Consensus | — | Rs 109 | 2026 |
The analyst target range for Vivimed Labs reflects genuine difference of opinion on demand recovery, margin trajectory and sector headwinds. The implied upside in the Vivimed Labs stock forecast from the current price of Rs 95 may or may not be realised by end of 2026.
3 Stocks Building Serious Momentum Right Now
When Univest analysts identify high-conviction stock opportunities, investors pay attention.
Our research team has shortlisted the Top Stocks to Buy based on current market momentum, sector trends & growth potential for 2026.
- Discover stocks investors are actively accumulating
- High-conviction opportunities backed by research
- Designed for the next phase of market growth
Unlock the latest Top Stock Picks now on Univest
Vivimed Labs Company Overview
Vivimed Labs is a significant player in India’s pharmaceutical industry with a presence across domestic formulations, US generics and specialty segments. The Vivimed Labs stock prediction for 2026 reflects both the pipeline growth potential and regulatory risk.
| Metric | Value |
|---|---|
| NSE Ticker | VIVIMEDLAB |
| Sector | Pharmaceuticals and Healthcare |
| CMP | Rs 95 (2026) |
| 52 Week High | — |
| 52 Week Low | — |
| Market Cap | — |
| P/E Ratio | — |
| Vivimed Labs Stock Prediction Consensus (12M) | Rs 109 |
Vivimed Labs Stock Prediction by Time Horizon
Analysts split the Vivimed Labs share price prediction across time frames as near-term drivers differ materially from the long-term view.
Short-Term Vivimed Labs Stock Prediction
The near-term Vivimed Labs stock forecast reflects current sentiment, sector news and upcoming earnings prints. Key support and resistance levels around Rs 95 are being watched closely. A short-term Vivimed Labs share price prediction carries the most uncertainty of any time horizon.
12-Month Vivimed Labs Stock Prediction
JM Financial targets Rs 115 (Neutral) and Kotak Securities targets Rs 102 (Neutral). Most desks refresh their Vivimed Labs stock forecast within two to four weeks of each quarterly earnings print. The Vivimed Labs share price prediction should be verified against the most recent analyst reports.
Long-Term Vivimed Labs Stock Prediction
The long-term outlook for Vivimed Labs is built on assumptions about demand recovery, margin expansion and revenue diversification in the Pharmaceuticals and Healthcare sector. Long-term price targets carry the most uncertainty and should be treated as directional guidance only.
Vivimed Labs Stock Forecast: Key Factors
The following four factors appear consistently in analyst research on Vivimed Labs and are the primary inputs into the bull and bear case scenarios.
US Generic Revenue
US generics revenue is the most watched metric in the Vivimed Labs stock forecast. USFDA approval timelines and price erosion rates directly affect the Vivimed Labs share price prediction from most research desks.
Domestic Formulations Growth
Domestic formulation growth provides a stable base that supports the Vivimed Labs stock prediction even when export growth faces headwinds.
R&D Pipeline
The depth and commercialization pace of the R&D pipeline is a key variable in the long-term Vivimed Labs share price prediction. New product approvals are cited as catalysts for the Vivimed Labs stock prediction.
EBITDA Margin
Sustained EBITDA margin expansion is typically the basis for the bullish Vivimed Labs stock forecast. Margin recovery strengthens the Vivimed Labs share price prediction from most research desks.
Vivimed Labs Stock Prediction: Bull and Bear Scenarios
| Scenario | Vivimed Labs Stock Prediction | Key Conditions |
|---|---|---|
| Bull Case | Rs 115 | Strong execution, margin improvement, favourable macro and sector re-rating |
| Base Case | Rs 109 | Steady performance, gradual recovery, margins hold, growth on track |
| Bear Case | Rs 92 | Demand deterioration, margin pressure, sector de-rating and macro headwinds |
The bull case Vivimed Labs stock forecast of Rs 115 assumes most positive variables converge. The base case of Rs 109 is the analyst consensus and may or may not be achieved.
How Analysts Are Reading the Vivimed Labs Stock Story
Analyst reviews of the Vivimed Labs share price prediction highlight the company’s core strengths in Pharmaceuticals and Healthcare alongside near-term headwinds from macro uncertainty, competitive pressure and sector-level challenges. Overall the analyst consensus for Vivimed Labs is built on real business strengths set against real risks.
Key Risks to the Vivimed Labs Stock Prediction
USFDA Regulatory Risk
Import alerts and warning letters from the USFDA are the most significant risks to the Vivimed Labs stock prediction. A facility closure would force an immediate sharp revision to the Vivimed Labs share price prediction.
Price Erosion in the US
Pricing pressure in US generics compresses the revenue per product and affects the Vivimed Labs stock forecast. Aggressive price erosion pushes the Vivimed Labs share price prediction toward the bear case.
R&D Execution Risk
Delays in clinical trials or approval failures affect the Vivimed Labs stock prediction. The Vivimed Labs share price prediction is particularly sensitive to key pipeline asset announcements.
Currency Risk
A strengthening rupee against the dollar reduces export realisation and affects the Vivimed Labs stock forecast. Currency risk is embedded in conservative Vivimed Labs share price prediction models.
How to Monitor the Vivimed Labs Stock Forecast
Track the Vivimed Labs share price prediction consensus quarterly. After every earnings release, most brokerages revise their Vivimed Labs stock forecast within two weeks. Comparing the revised analyst target to the previous estimate tells you whether sentiment on Vivimed Labs is improving or deteriorating.
Compare the current price of Rs 95 with the analyst target range of Rs 115 to Rs 102. A wide target band reflects genuine uncertainty on Vivimed Labs, so position size should reflect that range rather than the midpoint alone.
Review the Vivimed Labs share price prediction every quarter against key business metrics for the Pharmaceuticals and Healthcare sector. A single estimate from any analyst is a point-in-time view and should be treated as one input among many when making any investment decision.
Check Live Vivimed Labs Fundamentals on the Univest Screener
Conclusion
The Vivimed Labs stock prediction for 2026 reflects the analyst community’s assessment of Vivimed Labs’s competitive position, earnings trajectory and macro environment. JM Financial holds a Neutral stance with a target of Rs 115 while Kotak Securities has a Neutral rating with a target of Rs 102, giving an analyst consensus of Rs 109.
The Vivimed Labs stock forecast is set against near-term risks that make the Vivimed Labs share price prediction range wide. Investors should verify any estimate with the latest brokerage reports before using it as an investment reference. The analyst forecast will be revised after every quarterly result, so tracking how the Vivimed Labs share price target changes over time is more valuable than relying on any single estimate.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.
Download the Univest iOS App or Univest Android App to track live analyst targets, price movements and research updates for Vivimed Labs in real time.
Disclaimer: Data and figures in this article are sourced from publicly available information and may or may not be accurate. Analyst price targets are from public brokerage reports and should be independently verified. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Vivimed Labs Stock Prediction 2026
What is the Vivimed Labs stock prediction for 2026?
Ans. The Vivimed Labs stock prediction for 2026 is based on analyst consensus from JM Financial and Kotak Securities. The consensus target is Rs 109. All estimates may or may not be achieved.
Is the Vivimed Labs stock prediction bullish or bearish?
Ans. JM Financial has a Neutral rating with target Rs 115. Kotak Securities has a Neutral rating with target Rs 102. The Vivimed Labs stock forecast reflects genuine analyst diversity of opinion.
What is the Vivimed Labs share price prediction based on fundamentals?
Ans. The Vivimed Labs share price prediction rests on the US generic pipeline, domestic growth, EBITDA margin and regulatory compliance track record. Analysts tracking Vivimed Labs closely cite these as the primary drivers of the 2026 outlook.
What is the long-term Vivimed Labs stock prediction?
Ans. The long-term outlook assumes Vivimed Labs sustains its core business drivers over a multi-year horizon. The 12-month consensus of Rs 109 is the nearest reliable anchor point.
What are the key risks to the Vivimed Labs stock prediction?
Ans. The primary risks include sector-specific headwinds, macro uncertainty, regulatory changes and competitive pressure. Every analyst estimate for Vivimed Labs should be read alongside its risk assumptions.
What does the Vivimed Labs stock forecast say for 2026?
Ans. JM Financial: Neutral target Rs 115. Kotak Securities: Neutral target Rs 102. These Vivimed Labs share price prediction estimates may or may not prove accurate.
Where can I track the latest Vivimed Labs stock prediction?
Ans. Track the latest analyst targets and price movements for Vivimed Labs on the NSE and BSE websites and on the Univest app and screener for live data.
